We firstly confirmed the anti-fibrotic effect of Nintedanib in a double-hit BLM rat model of lung fibrosis through the downregulation of several molecular makers (including HYP, pro-collagen 1, WISP-1, and MMP-7, Collagen type 1 and Fibronectin), and the reduction in the Ashcroft scores and of the automated fibrosis quantification determined by a machine learning algorithm (Figure 2 and Section 4). The gene discussed is CCN4; the disease is pulmonary fibrosis.